HNN3.0
Register
Register
Register

BIOEMTECH

Company (SME)

bioemtech.com/Gerakas Attikis, Greece

About

BIOEMTECH is a high-tech company that offers innovative and at the same time affordable services and products in pharmaceutical and medical research. The company develops molecular imaging systems, provides services in Nuclear Medicine technology and has additional expertise on software medical solutions using AI techniques and MC simulations. BIOEMTECH laboratories are a rapidly growing CRO that offers a set of services related to pre-clinical research operating in a GLP environment. It covers a full chain of pre-clinical studies as follows: consulting and project management, cell testing (in vitro), animal model development, radiochemical protocol development for a wide range of isotopes and 'cold' chemistry tests, non-invasive molecular imaging studies in small laboratory animals (multi-modal in vivo imaging studies: optical, PET, SPECT, CT), advanced image processing, clinical chemistry tests, drug efficacy studies , GLP toxicology studies, ex vivo biodistributions as well as postmortem analyses.

Representatives

Science and Innovation Manager

BIOEMTECH

Marketplace (1)

  • Project cooperation

    Preclinical studies partner

    BIOEMTECH provides preclinical CRO services and advanced molecular imaging of small animals.

    • Partner seeks Consortium/Coordinator
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-15: Scaling up innovation in cardiovascular health
    • DESTINATION 2: HORIZON-HLTH-2026-01-ENVHLTH-04: Towards climate resilient, prepared and carbon neutral populations and healthcare systems
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-05: Pilot actions for follow-on funding: Leveraging EU-funded collaborative research in regenerative medicine
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-11: Understanding of sex and/or gender-specific mechanisms of cardiovascular diseases: determinants, risk factors and pathways
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices
    Author

    Science and Innovation Manager at BIOEMTECH

    Gerakas Attikis, Greece